AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37219859 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined BRAF/ERK1/2 inhibition
Number of subjects: 0
Study 37219865 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol (40 μg daily increased to 80 μg twice daily)
Number of subjects: 25
Study 37219901 — intervention group
Group type: EXPERIMENTAL
Intervention: AB-CASI (automated bilingual computerized alcohol screening and intervention)
Number of subjects: 840
Study 37219901 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 840
Study 37219901 — intervention group
Group type: EXPERIMENTAL
Intervention: AB-CASI (for participants older than 25 years)
Number of subjects: 840
Study 37219901 — intervention group
Group type: COMPARATOR
Intervention: Standard care (for participants older than 25 years)
Number of subjects: 840
Study 37219901 — intervention group
Group type: EXPERIMENTAL
Intervention: AB-CASI (for participants 25 years or younger)
Number of subjects: 840
Study 37219901 — intervention group
Group type: COMPARATOR
Intervention: Standard care (for participants 25 years or younger)
Number of subjects: 840
Study 37219930 — intervention group
Group type: COMPARATOR
Intervention: Stable isotope tracer methodology applied to liver slices and in vivo
Number of subjects: 5
Study 37219930 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression analysis
Number of subjects: 5
Study 37219970 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C for 24 hours
Number of subjects: 146
Study 37219970 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C for 24 hours
Number of subjects: 146
Study 37220008 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Antioxidant Capacity
Number of subjects: 0
Study 37220008 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 0
Study 37220015 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered care with annual population HIV testing and universal ART
Number of subjects: 893
Study 37220015 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment model (baseline population testing with ART by country standard)
Number of subjects: 893
Study 37220093 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6263
Study 37220093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study 37220094 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (cost-effective implementation)
Number of subjects: 0
Study 37220119 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortetropin® supplement (FOR-SUPP, n = 12) consuming 19.8 g/d of FOR
Number of subjects: 24
Study 37220119 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA-SUPP, n = 12) consuming energy- and macronutrient-matched cheese powder
Number of subjects: 24
Study 37220119 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (FOR-SUPP and PLA-SUPP) after 2-wk of single-leg immobilization
Number of subjects: 24
Study 37220119 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (FOR-SUPP and PLA-SUPP) after 2-wk of normal activity
Number of subjects: 24
Study 37220130 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA) of the incompetent saphenous trunk without tributary treatment
Number of subjects: 0
Study 37220130 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided foam sclerotherapy (UGFS) concomitantly with truncal ablation
Number of subjects: 0
Study 37220172 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 11005
Study 37220228 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 60
Study 37220228 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine
Number of subjects: 60
Study 37220236 — intervention group
Group type: EXPERIMENTAL
Intervention: C-LIFE intervention (4-month program of dietary counseling, behavioral weight management, and exercise)
Number of subjects: 140
Study 37220236 — intervention group
Group type: COMPARATOR
Intervention: SEPA (single counseling session providing standardized education and physician advice)
Number of subjects: 140
Study 37220236 — intervention group
Group type: EXPERIMENTAL
Intervention: C-LIFE intervention
Number of subjects: 140
Study 37220393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pecs block with ropivacaine
Number of subjects: 50
Study 37220393 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 50
Study 37220480 — intervention group
Group type: EXPERIMENTAL
Intervention: Casirivimab & imdevimab
Number of subjects: 265
Study 37220480 — intervention group
Group type: COMPARATOR
Intervention: Remdesivir
Number of subjects: 265
Study 37220480 — intervention group
Group type: COMPARATOR
Intervention: Favipravir
Number of subjects: 265
Study 37220640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate (low-osmolarity iodine contrast)
Number of subjects: 2268
Study 37220640 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (iso-osmolarity iodine contrast)
Number of subjects: 2268
Study 37220815 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 64
Study 37220815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 64
Study 37220815 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment CST close to estimated inflection points (217 to 256 μm)
Number of subjects: 64
Study 37220815 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy
Number of subjects: 64
Study 37220821 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted positioning of the LV lead towards the latest local electrical activation in the coronary sinus (CS)
Number of subjects: 1000
Study 37220821 — intervention group
Group type: COMPARATOR
Intervention: Conventional LV lead positioning preferably in a nonapical posterolateral branch of the coronary sinus (CS)
Number of subjects: 1000
Study 37220822 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 37220822 — intervention group
Group type: EXPERIMENTAL
Intervention: Study medications delivery
Number of subjects: 0
Study 37220822 — intervention group
Group type: EXPERIMENTAL
Intervention: Study visits adaptations
Number of subjects: 0
Study 37220822 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 related endpoint adjudication
Number of subjects: 0
Study 37220822 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol and analytical plan revisions
Number of subjects: 0
Study 37220893 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel alone
Number of subjects: 3211
Study 37220893 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with bevacizumab
Number of subjects: 3211
Study 37220958 — intervention group
Group type: EXPERIMENTAL
Intervention: microMend wound closure device
Number of subjects: 31
Study 37220998 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban combined with Aspirin
Number of subjects: 0
Study 37220998 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with Aspirin
Number of subjects: 0
Study 37221023 — intervention group
Group type: EXPERIMENTAL
Intervention: Value-based healthcare (VBHC) framework implementation
Number of subjects: 350
Study 37221022 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus sheath block (RSB)
Number of subjects: 110
Study 37221022 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 110
Study 37221022 — intervention group
Group type: EXPERIMENTAL
Intervention: RSB
Number of subjects: 110
Study 37221022 — intervention group
Group type: COMPARATOR
Intervention: TEA
Number of subjects: 110
Study 37221027 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight
Number of subjects: 25447
Study 37221027 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/Obese
Number of subjects: 25447
Study 37221027 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunting
Number of subjects: 25447
Study 37221027 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic status and empowerment
Number of subjects: 25447
Study 37221027 — intervention group
Group type: EXPERIMENTAL
Intervention: Wealth quintile and food security
Number of subjects: 25447
Study 37221027 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level and food security
Number of subjects: 25447
Study 37221030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ages and Stages Questionnaire (ASQ)
Number of subjects: 1034
Study 37221052 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 1260
Study 37221052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1260
Study 37221052 — intervention group
Group type: EXPERIMENTAL
Intervention: sNfL at attack
Number of subjects: 1260
Study 37221052 — intervention group
Group type: EXPERIMENTAL
Intervention: sGFAP, sTau, sUCHL1
Number of subjects: 1260
Study 37221146 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept
Number of subjects: 219
Study 37221177 — intervention group
Group type: EXPERIMENTAL
Intervention: Low bolus + low infusion (15 mg + 0.6 mg/min)
Number of subjects: 27
Study 37221177 — intervention group
Group type: EXPERIMENTAL
Intervention: High bolus + high infusion (25 mg + 1 mg/min)
Number of subjects: 27
Study 37221177 — intervention group
Group type: EXPERIMENTAL
Intervention: Low infusion (0.6 mg/min)
Number of subjects: 27
Study 37221177 — intervention group
Group type: EXPERIMENTAL
Intervention: High infusion (1 mg/min)
Number of subjects: 27
Study 37221177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 37221181 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab
Number of subjects: 123
Study 37221247 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTrans (allogeneic Wharton's jelly-derived mesenchymal stromal cells)
Number of subjects: 15
Study 37221247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 37221407 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1601
Study 37221407 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital pharmacotherapy optimization
Number of subjects: 1601
Study 37221430 — intervention group
Group type: COMPARATOR
Intervention: Circulating levels of follistatin
Number of subjects: 0
Study 37221430 — intervention group
Group type: COMPARATOR
Intervention: Circulating levels of FSTL3
Number of subjects: 0
Study 37221430 — intervention group
Group type: COMPARATOR
Intervention: Circulating levels of activin B
Number of subjects: 0
Study 37221430 — intervention group
Group type: COMPARATOR
Intervention: Circulating levels of activin AB
Number of subjects: 0
Study 37221430 — intervention group
Group type: COMPARATOR
Intervention: Activin AB/follistatin ratio
Number of subjects: 0
Study 37221430 — intervention group
Group type: COMPARATOR
Intervention: Activin AB/FSTL3 ratio
Number of subjects: 0
Study 37221447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training combined with social engagement
Number of subjects: 66
Study 37221447 — intervention group
Group type: COMPARATOR
Intervention: Social engagement group without training
Number of subjects: 66
Study 37221466 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated DENV3 monovalent vaccine rDEN3Δ30/31-7164
Number of subjects: 0
Study 37221613 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic reinterpretation of CNVs of uncertain significance
Number of subjects: 259
Study 37221704 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (n = 31)
Number of subjects: 61
Study 37221704 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 61
Study 37222099 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital psychological self-care
Number of subjects: 36
Study 37222151 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 117
Study 37222151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 37222189 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with mFOLFIRINOX
Number of subjects: 0
Study 37222189 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant treatments
Number of subjects: 0
Study 37222189 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant therapy
Number of subjects: 0
Study 37222189 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of all cycles of planned adjuvant chemotherapy
Number of subjects: 0
Study 37222204 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab as adjuvant treatment after curative surgery for oesophagal or gastroesophageal junction cancer
Number of subjects: 0
Study 37222204 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunotherapy in dMMR colorectal cancers
Number of subjects: 0
Study 37222252 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (40-60 mg/d)
Number of subjects: 363
Study 37222252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/d)
Number of subjects: 363
Study 37222252 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination ISMN-cilostazol (40-60 mg/d and 200 mg/d, respectively)
Number of subjects: 363
Study 37222252 — intervention group
Group type: COMPARATOR
Intervention: No study drug (control group)
Number of subjects: 363
Study 37222260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysosomal acid lipase deficiency (LAL-D) patients with elevated alanine aminotransferase levels
Number of subjects: 228
Study 37222260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysosomal acid lipase deficiency (LAL-D) patients with elevated aspartate aminotransferase levels
Number of subjects: 228
Study 37222260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysosomal acid lipase deficiency (LAL-D) patients with hepatomegaly
Number of subjects: 228
Study 37222260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysosomal acid lipase deficiency (LAL-D) patients with dyslipidaemia
Number of subjects: 228
Study 37222260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysosomal acid lipase deficiency (LAL-D) patients with liver biopsies
Number of subjects: 228
Study 37222260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysosomal acid lipase deficiency (LAL-D) patients with fibrosis-stage data
Number of subjects: 228
Study 37222267 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 0
Study 37222267 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37222316 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 25
Study 37222316 — intervention group
Group type: COMPARATOR
Intervention: Resupine position
Number of subjects: 25
Study 37222316 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 25
Study 37222324 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia for cesarean section
Number of subjects: 906
Study 37222324 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency surgery
Number of subjects: 906
Study 37222324 — intervention group
Group type: EXPERIMENTAL
Intervention: Early gestational weeks
Number of subjects: 906
Study 37222324 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates <3rd weight percentile
Number of subjects: 906
Study 37222328 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal salivary cortisol level ≤24.20
Number of subjects: 400
Study 37222328 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal cortisol levels
Number of subjects: 400
Study 37222468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracanal cryotherapy (2.5°C)
Number of subjects: 44
Study 37222468 — intervention group
Group type: COMPARATOR
Intervention: Control (room temperature distilled water)
Number of subjects: 44
Study 37222476 — intervention group
Group type: EXPERIMENTAL
Intervention: Early anticoagulation (within 48 hours after a minor or moderate stroke or on day 6 or 7 after a major stroke)
Number of subjects: 2013
Study 37222476 — intervention group
Group type: COMPARATOR
Intervention: Later anticoagulation (day 3 or 4 after a minor stroke, day 6 or 7 after a moderate stroke, or day 12, 13, or 14 after a major stroke)
Number of subjects: 2013
Study 37222476 — intervention group
Group type: EXPERIMENTAL
Intervention: Early anticoagulation
Number of subjects: 2013
Study 37222476 — intervention group
Group type: COMPARATOR
Intervention: Later anticoagulation
Number of subjects: 2013
Study 37222628 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial function testing using EndoPAT 2000
Number of subjects: 300
Study 37222663 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct R0 without further resection
Number of subjects: 679
Study 37222663 — intervention group
Group type: EXPERIMENTAL
Intervention: Converted R0 after positive intraoperative pathology consultation (IOC) and extension of resection
Number of subjects: 679
Study 37222663 — intervention group
Group type: COMPARATOR
Intervention: R1 status
Number of subjects: 679
Study 37222663 — intervention group
Group type: COMPARATOR
Intervention: Converted R0
Number of subjects: 679
Study 37222671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-COVID
Number of subjects: 271
Study 37222671 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-COVID
Number of subjects: 271
Study 37222671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pan University Hospital rotations
Number of subjects: 271
Study 37222685 — intervention group
Group type: EXPERIMENTAL
Intervention: Resected lymph nodes (24 or more) in patients with positive lymph nodes (N+)
Number of subjects: 1624
Study 37222685 — intervention group
Group type: EXPERIMENTAL
Intervention: Resected lymph nodes (15-23) in patients with positive lymph nodes (N+)
Number of subjects: 1624
Study 37222685 — intervention group
Group type: COMPARATOR
Intervention: Resected lymph nodes (N0 group)
Number of subjects: 1624
Study 37222717 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Shock Index multiplied by the Glasgow Coma Scale (rSIG)
Number of subjects: 105641
Study 37222717 — intervention group
Group type: COMPARATOR
Intervention: Shock Index (SI)
Number of subjects: 105641
Study 37222717 — intervention group
Group type: COMPARATOR
Intervention: Modified Shock Index (MSI)
Number of subjects: 105641
Study 37222716 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating extracellular vesicles-derived lncRNA-GC1
Number of subjects: 798
Study 37222716 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating extracellular vesicles-derived lncRNA-GC1 response
Number of subjects: 798
Study 37222787 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled breakfast containing H
Number of subjects: 6
Study 37222865 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' perspectives
Number of subjects: 165
Study 37222865 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant others' perspectives
Number of subjects: 165
Study 37222865 — intervention group
Group type: EXPERIMENTAL
Intervention: GPs' perspectives
Number of subjects: 165
Study 37222865 — intervention group
Group type: EXPERIMENTAL
Intervention: District nurses' perspectives
Number of subjects: 165
Study 37222865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital physicians' perspectives
Number of subjects: 165
Study 37222865 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater agreement between patient-significant other dyads
Number of subjects: 165
Study 37222865 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater agreement between GP-hospital physician dyads
Number of subjects: 165
Study 37223015 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG angiography-guided thyroidectomy
Number of subjects: 0
Study 37223015 — intervention group
Group type: COMPARATOR
Intervention: Conventional thyroidectomy
Number of subjects: 0
Study 37223263 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy (NC)
Number of subjects: 0
Study 37223263 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 37223390 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS over the DMPFC
Number of subjects: 49
Study 37223390 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS-synchronized transcutaneous electrical nerve stimulation
Number of subjects: 49
Study 37223438 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab
Number of subjects: 376
Study 37223438 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab
Number of subjects: 376
Study 37223438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study 37223439 — intervention group
Group type: EXPERIMENTAL
Intervention: AXA1125 (33.9 g, administered orally in a liquid suspension twice daily for four weeks)
Number of subjects: 41
Study 37223439 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo administered orally in a liquid suspension twice daily for four weeks)
Number of subjects: 41
Study 37223507 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
Number of subjects: 6
Study 37223507 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 6
Study 37223611 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily
Number of subjects: 120
Study 37223611 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 120
Study 37223611 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 120
Study 37223611 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 120
Study 37223613 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas chromatography-mass spectrometry (GC-MS) for measuring breath VOCs in obese children with dyslipidemia.
Number of subjects: 82
Study 37223666 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg OD for 14 days
Number of subjects: 660
Study 37223666 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 660
Study 37223666 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 660
Study 37223666 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 660
Study 37223900 — intervention group
Group type: EXPERIMENTAL
Intervention: RAMP-HT
Number of subjects: 212707
Study 37223900 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 212707
Study 37223933 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 5815